CN: 32-1845/R
ISSN: 2095-6975
引用本文:
0
LIU Qin, WANG Shun-Chun, DING Kan. Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine[J]. 中国天然药物英文, 2017, 15(9): 641-652

Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine

LIU Qin1,2,3,4, WANG Shun-Chun1, DING Kan2,3,4
1 Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2 Glycochemistry and Glycobiology Lab, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
3 University of Chinese Academy of Sciences, Beijing 100049, China;
4 Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
摘要:
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the loss of patients' memory and their cognitive abilities and the mechanism is not completely clear. Although a variety of drugs have been approved for the AD treatment, substances which can prevent and cure AD are still in great need. The effect of polysaccharides from traditional Chinese medicine (TCM) on anti-AD has gained great progress and attained more and more attention in recent years. In this review, research advances in TCM-polysaccharides on AD made in this decade are summarized.
关键词:    Alzheimer's disease    Polysaccharides    Traditional Chinese medicine   
收稿日期: 2016-12-23
WANG Shun-Chun,Tel:86-21-51322511,Fax:86-21-51322519,E-mail:shunchunwang@126.com;DING Kan,Tel/Fax:86-21-50806928,E-mail:dingkan@simm.ac.cn.
相关功能
PDF(582 KB) Free
打印本文
把本文推荐给朋友
作者相关文章
LIU Qin 在本刊中的所有文章
WANG Shun-Chun 在本刊中的所有文章
DING Kan 在本刊中的所有文章
参考文献:
[1] Selkoe DJ. Preventing Alzheimer's disease[J]. Science, 2012, 337(6101):1488-1492.
[2] Culter NR, Sramek JJ. Review of the nest generation of Alzheimer's disease therapeutics:challenges for drug development[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2001, 25(1):27-57.
[3] Mattson MP. Pathways towards and away from Alzheimer's disease[J]. Nature, 2004, 430(7000):631-639.
[4] Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies[J]. Cell, 2012, 148(6):1204-1222.
[5] Bertram L, Tanzi RE. The genetic epidemidogy of neurodegenerative disease[J]. J Clin Invest, 2005, 115(6):1449-1457.
[6] Gerald Z, Ockert W. Alzheimer's disease market:hope deferred[J]. Nat Rev Drug Discov, 2013, 12(1):19-20.
[7] Bateman R. Alzheimer's disease and other dementias:advances in 2014[J]. Lancet Neurol, 2015, 14(1):4-6.
[8] Lepenies B, Seeberger PH. The promise of glycomics, glycan arrays and carbohydrate-based vaccines[J]. Immunopharmacol Immunotoxicol, 2010, 32(2):196-207.
[9] Shukla RK, Tiwari A. Carbohydrate molecules:an expanding horizon in drug delivery and biomedicine[J]. Crit Rev Ther Drug Carrier Syst, 2011, 28(3):255-292.
[10] LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease[J]. Nat RevNeurosci, 2007, 8(7):499-509.
[11] Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease:from synapses toward neural networks[J]. Nat Neurosci, 2010, 13(7):812-818.
[12] Wang J, Lu R, Yang J, et al. TRPC6 specifically interacts with APP to inhibit its cleavage by gamma-secretase and reduce A beta production[J]. Nat Commun, 2015, 6:8876.
[13] Deepak KV, Choi SH, Washicosky KJ, et al. Amyloid-b peptide protects against microbial infection in mouse and worm models of Alzheimer's disease[J]. Sci Transl Med, 2016, 8(340):340ra72.
[14] Wang PP, Liao WF, Fang JP, et al. A glucan isolated from flowers of Lonicera japonica Thunb. inhibits aggregation and neurotoxicity of A beta(42)[J]. Carbohydr Polym, 2014, 110:142-147.
[15] Yang F, Zhou Y, Sheng L, et al. Effect of polysaccharide from Vitis viniferal on expression of APP in Alzheimer's disease cell model[J]. Chin J Exper Tradit Med Formul, 2015, 21(18):107-110.
[16] Chu SH, Hu HY, Chen X, et al. Effect of qing xin kaiqiaofang and polysaccharide on the expression of the apoptosis signal transtuduetion molecule caspase-3 and apoptosis associated gens Bax\Bcl-2 in brain of AD rats[J]. Chin J Basic Med Tradit Chin Med, 2012, 8:841-844.
[17] Hu HY, Tan ZW, Chen X, et al. Effect of qing xin kaiqiaofang and polysaccharide on the expression of GFAP amd βAPP in hippocampus of AD rats[J]. Zhejiang J Tradit Chin Med, 2012, 7:492-493.
[18] Xiao F, Li XG, Gao Q, et al. The inhibition of amyloid beta-protein production in M146L cell by Kadsura heteroclita polysaccharide[J]. Chin J Gerontol, 2009, 19:2458-2460.
[19] Huang ZS, Jiao Y, Zhang SJ, et al. Effect of LYS polysaccharides on dementia-related gene expressions in SAMP8 mouse brain[J]. Chin Pharmacol Bullet, 2008, 4:509-512.
[20] Yi YX, Wu SX, Ye SM, et al. Effect of Abeta1-42 injection on hippocampus cells in rats and protective role of polygona-polysaccharose for Alzheimer's disease[J]. J Centr South Univer Med Sci, 2014, 39(4):344-348.
[21] Li YP, Wang XY, Chen J, et al. Influence of ganoderma lucidum polysaccharides peptide on β-amyloid peptide and tau's hyperphosphorylation in rat with Alzheimer's disease[J]. J Chin Prat Diag Ther, 2015, 9:862-865.
[22] Fei H, Gao Y, Sun L. Effect of astragalus polysaccharides on the hippocampal tissue in Alzheimer's disease mouse[J]. Chin J Gerontol, 2015, 35(16):4426-4429.
[23] Jiang RW, Du XG, Zhang X, et al. Synthesis and bioassay of beta-(1, 4)-D-mannans as potential agents against Alzheimer's disease[J]. Acta Pharmacol Sin, 2013, 34(12):1585-1591.
[24] Shin RW, Iwaki T, Kitamoto T, et al. Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues[J]. Lab Invest, 1999, 64(5):693-702.
[25] Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene[J]. Biochemistry, 1992, 31(43):10626-10633.
[26] Alonso A, Zaidi T, Novak M, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments[J]. Proc Natl Acad Sci, 2001, 98(12):6923-6928.
[27] Dermaut B, Kumar-Singh S, Rademakers R, et al. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum[J]. Trends Genet, 2005, 21(12):664-672.
[28] Brier MR, Gordon B, Friedrichsen K, et al. Tau and A beta imaging, CSF measures, and cognition in Alzheimer's disease[J]. Sci Transl Med, 2016, 8(338):338ra66.
[29] Taniguchi T, Kawamata T, Mukai H, et al. Phosphorylation of tau is regulated by PKN[J]. J Biol Chem, 2001, 276(13):10025-10031.
[30] Mudher M, Lovestone S. Alzheimer's disease-do tauists and Baptists finally shake hands?[J]. Trends Neurosci, 2002, 25(1):22-26.
[31] Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics[J]. BMC Med, 2009, 7:7.
[32] Su YN, Chen LQ, Zhang XB, et al. Effect of polysaccharide from Comus officinalis on GSK-3β and phosphorylated GSK-3β in Alzheimer's disease mouse[J]. Chin J Gerontol, 2013, 9:2092-2094.
[33] Yao HT, Ma JL, Zhang XB, et al. Effect of polysaccharide from Comus officinalis on Tau protein in Alzheimer's disease mouse[J]. Chin JGerontol, 2013, 12:2838-2841.
[34] Chen XY, Rong YP, Guo YJ, et al. Effects of Millettia pulcha polysaccharides on neuronal loss and tau phosphorylation in frontal lobe and hippocampus of SAMP8 mice[J]. Chin J Expr Tradt Med Formul, 2013, 9:181-184.
[35] Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology:Neurotransmitters, Synapses, and Impulse Transmission[M]. W. H. Freeman, New York, 2000.
[36] Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease:a review of progress[J]. J Neurol Neurosurg Psychiatry, 1999, 66(2):137-147.
[37] Phillis JW. Acetylcholine release from the central nervous system:A 50-year retrospective[J]. Crit Rev Neurobiol, 2005, 17(3-4):161-217.
[38] Taylor P, Radić Z. The cholinesterases:from genes to proteins[J]. Annu Rev Pharmacol Toxicol, 1994, 34:281-320.
[39] Schliebs R, Arendt T. The cholinergic system in aging and neural degradation[J]. Behav Brain Res, 2011, 221(2):555-563.
[40] Nyakas C, Granic I, Halmy L, et al. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-B42 with memantine[J]. Behav Brain Res, 2011, 221(2):594-603.
[41] Li XY, An FY, Li SG, et al. Effects of Angelica polysaccharides on calcium overloads and cholinergic neurons injury in senile dementia mice[J]. J Tradit Chin Med, 2013, 3:68-70.
[42] Yin G, Gong DK, Liu BH, et al. Effect of polysaccharides of Cistanche Deserticola on learning and memory ability and cholinergic system of model rats with Alzhermer's disease[J]. Neur Injur Funct Reconst, 2014, 5:426-427.
[43] Zhao TT, Zhang QB, Zhang ZS, et al. Effect of fucoidan on cognitive ability and cerebral cholinergic system in mice with Alzheimer's disease[J]. Tradit Chin Drug Res Clin Pharmacol, 2010, 2:160-163.
[44] Liu Z, Wan P, Gao J. Effects of Astragalus polysaccharides on learning and memory in vascular dementia mice[J]. J Jilin Med Col, 2014, 1:14-16.
[45] Sohal RS, Allen RG. Oxidative stress as a causal factorin differentiation and aging-aunifyinghy pothesis[J]. Experi Gerontol, 1990, 25(6):499-522.
[46] Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease[J]. Int J Biochem Cell Biol, 2007, 39(1):44-84.
[47] Kandel ER, Schwartz JH, Jessell TM. Principles of Neural Science[M]. New York:McGraw-Hill, 2000.
[48] Pardridge WM. The blood-brain barrier:Bottleneck in brain drug development[J]. NeuroRx, 2005, 2(1):3-14.
[49] Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease[J]. J Alzheimers Dis, 2010, 19(1):341-353.
[50] Tamagno E, Guglielmotto M, Aragno M, et al. Oxidative stress activates a positive feedback between the gamma-and betasecretase cleavages of the beta-amyloid precursor protein[J]. J Neurochem, 2008, 104(3):683-695.
[51] Sies H. Oxidative stress:oxidants and antioxidants[J]. Exp Physiol, 1997, 82(2):291-295.
[52] Zhong L, Wang ZF. Effects of yam polysaccharide on antioxidant capacity of mice with Alzheimer's disease[J]. Chin J Appli Physiol, 2015, 31(1):42-48.
[53] Chen XY, Rong YP, Zhang SJ, et al. Protective effects of YLS polysaccharides on Aβ25-34 induced apoptosis in PC12 cells[J]. Chin J Hospit Pharm, 2013, 11:837-840.
[54] Chen XY, Rong YP, Zhang SJ, et al. Protective effects of YLS polysaccharides on Aβ25-34 induced PC12 cells injury[J]. Chin Pharm, 2013, 19:1735-1738.
[55] Li XY, Chen KB, Zhang LY. Effects of angelica polysaccharide on behavior, SOD and telomerase activity in serum and brain of senile mice model[J]. Moder Tradit Chin Med, 2013, 2:101-104.
[56] Huang ZS, Lin X, Li J, et al. Effect of LYS polysaccharide on NO, SOD and MDA in brain of dementia mice induced by D-galactose[J]. Chin J Gerontol, 2005, 2:176-177.
[57] Yang XY. The effects of refined Polygonum Multiflorum Thunb. polysaccharide on learning memory and the activities of enzymes in the brain for the experimental mice with dementia[J]. Prog Pharmaceut Sci, 2005, 12:557-559.
[58] Liang YS, Ma L. Effect of Radix polygoni multiflori preparata polycose on senile dementia in rabbit model[J]. Inner Mongolia Med J, 2007, 1:15-17.
[59] Yin G, Gong DK, Liu BH, et al. Effect of polysaccharides of Cistanche Deserticola on learning and memory ability and oxygen stress of model rats with Alzhermer's disease[J]. J Apopl Ner Dis, 2013, 6:504-507.
[60] Yan T, Chen SB, Xu L, et al. Effect of ganoderma lucidum polysaccharides on learning and memory ability and oxygen stress of model rats with Alzheimer's disease[J]. Shanxi Med J, 2011, 4:387-389.
[61] Guo YJ, Yuan H, Zhang LN, et al. Effects of Ganoderma Lucidum polysaccharides on antioxidant ability and modality in the hippocampus of AD rats[J]. Acta Anatom Sin, 2006, 5:509-513.
[62] Tian SM, Ma YX, Sun LZ, et al. Effects of different fractions of Acori graminei rhizoma extracts on learning and memory abilities in Aβ-induced Alzheimer's disease mice[J]. Chin J Pathophysiol, 2012, 1:159-162.
[63] Lu AM, Yu TG. Protective effect of Lentinan on the neuron in the AD mouse induced by glutamate[J]. Chin J Gerontol, 2008, 4:337-339.
[64] Wu F, Zhu DN, Lin ZH, et al. Study on material basis and mechanism of action dangguishaoyaosan in the prevention and treatment of senile dementia IX:The anti-oxidative activity of the polysaccharides of FBD[J]. Chin J Exper Tradit Med Formul, 2007, 7:23-26.
[65] Xu AX, Wang CQ, Yang SH, et al. The synergistic effect on antisenility and its mechanism of PFR and PBWF[J]. J Lanzhou Univer Med Sci, 2005, 2:13-16.
[66] Reitz C, Mayeux R. Alzheimer disease:epidemiology, diagnostic criteria, risk factors and biomarkers[J]. Biochem Pharmacol, 2014, 88(4):640-651.
[67] Obulesu M, Lakshmi MJ. Apoptosis in Alzheimer's disease:an understanding of the physiology, pathology and therapeutic avenues[J]. Neurochem Res, 2014, 39(12):2301-2312.
[68] Sureda FX, Junyent F, Verdaguer E, et al. Antiapoptotic drugs:atherapautic strategy for the prevention of neurodegenerative diseases[J]. Curr Pharm Design, 2011, 17(3):230-245.
[69] Camins A, Sureda FX, Junyent F, et al. An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders[J]. Expert Opin Inv Drug, 2010, 19(5):587-604.
[70] Yu MS, Lai SW, Lin KF, et al. Characterization of polysaccharides from the flowers of Nerium indicum and their neuroprotective effects[J]. Int J Mol Med, 2004, 14(5):917-924.
[71] Yu MS, Wong AYY, So KF, et al. New polysaccharide from Nerium indicum protects neurons via stress kinase signaling pathway[J]. Brain Res, 2007, 1153:221-230.
[72] Chen XY, Effects of YLS polysaccharides on Aβ25-35 induced PC12 cells apoptosis[J]. Seek Med, 2013, 6:4-5.
[73] Chen XY. Huang RB. Effects of Yulangsan polysaccharides on caspase-3 exression and activity in the frontal lobe and hippocampus of SAMP8 mice[J]. Chin J Exper Tradit Med Formul, 2013, 13:208-211.
[74] Li XY, Chen KB, Zhang LY. Effects of angelica polysaccharides on learnign and memory abitlity as well as apoptosis in senile mouse model[J]. J Tradit Chin Med, 2013, 6:68-71.
[75] Tang CR, Cao GZ, Ye XL. Effect of Sargassum fusiforme polysaccharide on the ethology and expressions of Bcl-2 and Bax in brain tissue for Alzheimer's disease rat model[J]. Chin Arch Tradit Chin Med, 2012, 8:1832-1834.
[76] Yuan F, Xi Q, Sheng L, et al. The effects of polysaccharides from Vitis viniferal L. on apoptosis of PC12 cells induced by Aβ25-35[J]. Chin J Gerontol, 2015, 19:5372-5373.
[77] Li G, Yuan H, Li L, et al. Effects of ganoderma lucidum polysaccharides on c-Fos expression in the hippocampus of alzheimer's disease model rats[J]. Chin J Histochem Cytochem,2007, 6:727-732.
[78] Zhang YP, Yuan H, Li L, et al. Effects of ganoderma lucidum polysaccharides on caspase-3 and FasL expressions in the hippocampus of Alzheimer's disease model rats[J]. Chin J Histochem Cytochem, 2008, 5:484-489.
[79] Guo YJ, Li P, Yuan H. Relationship between effects of ganoderma lucidum polysaccharides on learning and memory in Alzheimer's disease rats and apoptosis of hippocampus cells[J]. Chin J Anat, 2008, 3:376-378.
[80] Yuan DJ, Zhang YF, Yao CX. Effects of Ganoderma lucidum polysaccharides on synapsis and hippocampal synaptophysin expression in Alzheimer's rats model[J]. Chin J Exper Tradit Med Formul, 2011, 3:151-155.
[81] Yin G, Gong DK, Liu BH, et al. Effect of polysaccharides of Cistanche Deserticola on learning and memory ability and Bcl-2 and caspase-3 expression in hippocampal neuron of model rats with Alzhermer's disease[J]. Lishizhen Med Mat Med Res, 2013, 5:1091-1092.
[82] Yi YX, Wu SX, Ye SM, et al. Effect of polygonatum polysaccharide on the apoptosis of hippocampal cells in Alzheimer's disease mouse induced by Aβ1-42[J]. Chin J Gerontol, 2015, 4:1044-1045.
[83] Chen DL, Zhang P, Lin L, et al. Effect of oligosaccharides from Morinda Officinalis on beta-amyloid-induced learning and memory dysfunction in rats[J]. Chin Pharmacol Bull, 2013, 2:271-276.
[84] Huang JY, Tu XY, Lou LY, et al. Pharmacological study on the antisenility effects of Erjingling[J], China J Chin Mater Med, 1998, 23(12):748-749
[85] Xu LL, Cheng YJ, Li J, et al. Neuroprotective effect of polysaccharides from Erjingling Prescription on hippocampal neuron apoptosis indeced by glytamate[J]. Chin J Pharmacol Toxicol, 2008, 2:124-128.
[86] Yu MS, Leung SK, Lai SW, et al. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity[J]. Exper Gerontol, 2005, 40(8-9):716-727.
[87] Ho YS, Yu MS, Lai CS, et al. Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on beta-amyloid peptide neurotoxicity[J]. Brain Res, 2007, 1158:123-134.
[88] Lai SW, Yu MS, Yuen WH, et al. Novel neuroprotective effects of the aqueous extracts from Verbena officinalis Linn.[J]. Neuropharmacology, 2006, 50(6):641-650.
[89] Khachaturian ZS. Calcium, membranes, aging, and Alz-heimer's disease. Introduction and overview[J]. Ann N Y Acad Sci, 1989, 568:1-4
[90] LaFerla FM. Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease[J]. Nat Rev Neurosci, 2002, 3(11):862-872.
[91] Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain ageing and Alzheimer's disease:minding the store[J]. Aging Cell, 2007, 6(3):307-317.
[92] Berridge MJ. Calcium hypothesis of Alzheimer's disease[J]. Pflugers Arch, 2010, 459(3):441-449.
[93] Fedrizzi L, Carafoli E. Ca2+ dysfunction in neurodegenerative disorders:Alzheimer's disease[J]. Biofactors, 2011, 37(3):189-196.
[94] Chen XY, Huang RB. Effects of YLS polysaccharides on intracellular calcium concentration in AD cell model[J]. Chin J New Clin Med, 2013, 7:613-615.
[95] Huang ZS, Lin X, Zhang SJ, et al. Effects of LYS polysaccharides on learning and memory as well as monoamine neurotransmitter conten in SAMP8 mice's brain[J]. Chin Pharm, 2008, 9:647-649.
[96] Li YS, Li TQ, Liang S, et al. Effects of astragalus polysaccharides on spatial learning and memory ability in rats with vascular dementia[J]. Hournal Med Sci Yanbian Univer, 2013, 2:92-94.
[97] Chen K, Geng MY, Guan HS, et al. The effect of sulfated polysaccharides from brown seaweeds GS201 on neuronal survival in embryonic wistar rats[J]. Chin J Mar Drug, 2001, 1:20-22.
[98] Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease[J]. Br J Pharmacol, 2011, 164(4):1285-1300.
[99] Kaushal A, Wani WY, Anand R, et al. Spontaneous and induced nontransgenic animal models of AD:modeling AD using combinatorial approach[J]. Am J Alzheimers Dis Other Demen, 2013, 28(4):318-326.
[100] Dong W, Wang R. Research progress on animal models of Alzheimer's disease[J]. Chin J Contemp Neurol Neurosur, 2015, 15(8):610-614.
[101] Huang ZS, Jiao Y, Zhang SJ, et al. Improving effects of LYS polysaccharides on learning and memory in senile dementia SAMP8 mice[J]. Chin J Gerontol, 2008, 21:2086-2088.
[102] Zhan LB, Zhong JH, Lu XG, et al., Protective effects of serum containing Zibu Piyin Recipe on neuron in endoplasmic reticulum and its mechanism study[J], J Chin Integr Med, 2007, 5(4):445-450
[103] Zhu LY, Zhang L, Zhan LB, et al. The effects of Zibu Piyin Recipe components on scopolamine-induced learning and memory impairment in the mouse[J]. J Ethnopharmacol, 2014, 151(1):576-582.
[104] Wng HH, Liu WH, Sun W, et al. Clinical research status of huperzine A for the treatment of Alzheimer's disease[J]. Chin J New Drug, 2011, 11:993-998.
[105] Rafii MS, Walsh S, Little JT, et al. A phase Ⅱ trial of huperzine A in mild to moderate Alzheimer's disease[J]. Neurology, 2011, 76(16):1389-1394.
[106] Wang BS, Wang H, Wei ZH, et al. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease:an updated meta-analysis[J]. J Neural Transm, 2009, 116(4):457-465.
[107] Cummings J, Aisen PS, DuBois B, et al. Drug development in Alzheimer's disease:the path to 2025[J]. Alzheimers Res Ther, 2016, 8:39.
[108] Muller T, Foley P. Clinical drug research in chronic central neurodegenerative disorders[J]. Expert Rev Neurother, 2016, 16(5):497-504.
[109] Peng Y, Li PP, Li L, et al. Progresss of clinical trials in Alzheimer's disease[J]. Acta Pharmaceut Sin, 2016, 51(8):1185-1195.
[110] Geng MY, A new drug for Alzheimer's disease:Mannan oligosaccharides[J]. Chin J Pharm Toxicol, 2017, 5:459-460.
[111] Greig SL. Memantine ER/donepezil:A review in Alzheimer's disease[J]. CNS Drugs, 2015, 29(11):963-970.
[112] Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease[J]. Drug Des Devel Ther, 2016, 10:3267-3279.